Sangamo Therapeutics, Inc. and Voyager Therapeutics, Inc. announced the parties have entered into a definitive license agreement for a potential treatment of prion disease. Using its proprietary epigenetic regulation platform, Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) which it believes can specifically and potently block expression of the prion protein, the pathogenic driver of prion disease. Sangamo's ZF-TRs have been shown in animal models to significantly reduce expression of the prion protein in the brain, extend life span and limit formation of toxic prion aggregates.

Under the agreement, Voyager has provided Sangamo with access to a capsid derived from Voyager's proprietary TRACER(TM) platform. Under the terms of the agreement, Sangamo has received a non-exclusive license to combine a Voyager TRACER capsid with Sangamo's ZF- TRACERs designed to treat prion disease. Sangamo is solely responsible for the research, development, manufacture and commercialization of any product candidates using the Voyager capsid.

These forward-looking statements include, without limitation, statements relating to zinc finger transcriptional regulators' potential to specifically and potently block expression the prion protein, the development of a potential treatment for prion disease through epigenetic regulation of the prion protein and the occurrence and timing of a potential IND submission in 2025. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research and development process, including the results of clinical trials; the regulatory approval process for product candidates; and the potential for technological developments that obviate technologies used by Sangamo and Voyager; the COVID-19 pandemic; the potential for Voyager to breach or terminate its agreement with Sangamo; and the potential for Sangamo to fail to realize its expected benefits of the Voyager agreement.

Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business.